Failure to Monitor Psychotropic Medication Side Effects
Summary
The facility failed to ensure adequate monitoring for psychotropic medication effectiveness, side effects, and adverse effects for five residents reviewed for unnecessary medications. Resident #1 had diagnoses including end stage renal disease, gastrointestinal hemorrhage, COPD, type 2 diabetes mellitus, and major depressive disorder, and was ordered Xanax and duloxetine. Although the care plan identified a risk for psychotropic side effects and included monitoring interventions, the MAR and TAR for March 2026 showed no monitoring for side effects of psychotropic medications. Resident #11 was admitted with Alzheimer’s disease, dementia with behaviors, dementia with psychotic disturbances, anxiety, and depression, and had orders for lorazepam and risperidone. The care plan identified risks for side effects of psychotropic medications and listed multiple potential adverse effects to observe for, but the MAR and TAR were silent for any medication side effect monitoring. Resident #12 had diagnoses including Alzheimer’s, schizophrenia, anxiety, and psychotic disorder with hallucinations, and was prescribed Ativan, Zoloft, and Buspar. The quarterly MDS showed cognitive impairment and behaviors, and the care plan addressed psychotropic side effects, but the MAR and TAR for February, March, and April 2026 contained no orders or mechanism for monitoring behaviors or side effects. Resident #44 had diagnoses including polyneuropathy, hypoxemia, morbid obesity, rheumatic heart disease, major depressive disorder, and anxiety, and was ordered Zoloft, mirtazapine, and buspirone. Resident #62 had diagnoses including metabolic encephalopathy, psychotic disorder with delusions, anxiety, type 2 diabetes mellitus, hypertension, and dementia, and was ordered Zoloft and Nuplazid. For both residents, the care plans identified psychotropic medication risks, but the MAR and TAR for March 2026 showed no monitoring for side effects. Staff interviews confirmed the facility did not conduct routine monitoring for behaviors or psychotropic medication side effects, and staff stated there was no specific place in the electronic charting to verify such assessments. The facility policy titled Unnecessary Drugs stated each resident’s drug regimen should be reviewed on an ongoing basis with adequate monitoring for efficacy and adverse consequences.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release July 29, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.